Luxfer Holdings PLC
NYSE:LXFRIndustrial - Machinery
+$0.51 today
- Market cap
- $464.28M
- Beta
- 1.12
- P/E (TTM)
- 86.4
- EPS (TTM)
- $0.22
- Dividend yield
- 2.76%
Volume 0.58M
Average 0.18M
LXFR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Luxfer Holdings PLCNYSE: LXFR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.4M rose 27.3% year over year, ahead of the +7.0% change in trailing-twelve-month research & development. Sequentially, it rose 16.7% from the prior quarter. Over 3 fiscal years it compounded at -4.3% a year.
Context
- Research & development amounted to 1.1% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +27.3% holds above the trailing-twelve-month pace of +7.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 4.3M USD
- Year-over-year change
- -2.3%
- 4-year CAGR
- +2.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.3M | -2.3% |
| FY2024 | 2024-12-31 | 4.4M | -4.3% |
| FY2023 | 2023-12-31 | 4.6M | -6.1% |
| FY2022 | 2022-12-31 | 4.9M | +25.6% |
| FY2021 | 2021-12-31 | 3.9M | — |
Research & Development vs competitors
How LXFR compares with its peers on the latest reported figures
- LXFR's LTM Mar 2026 research & development of $4.6M is the 2nd highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +7.0% is the 2nd highest of 6, against a peer median of -91.0%.
- Research & development amounts to 1.2% of revenue for LXFR, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $165.5M | +68.0% | +73.8% | — | |
| LTM Mar 2026 | $4.6M | +7.0% | -4.3% | 1.2% | |
| LTM Mar 2026 | $1.95M | -61.5% | -17.1% | 0.3% | |
| LTM Mar 2026 | $382K | -91.0% | -35.3% | 0.4% | |
SBCSBC Medical Group Holdings Incorporated | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | -5.8% | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding LXFR) | $0 | -91.0% | -11.4% | 0.0% | |
Competitors are the stored peer set for LXFR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 374.1M | 423.4M | 405M | 391.9M | 384.6M |
| Cost of Revenue | 278.1M | 328.4M | 328.4M | 306.2M | 295.4M |
| Gross Profit | 96M | 95M | 76.6M | 85.7M | 89.2M |
| Gross Margin | 25.7% | 22.4% | 18.9% | 21.9% | 23.2% |
| Research & Development | 3.9M | 4.9M | 4.6M | 4.4M | 4.3M |
| Selling, General & Admin | 47.3M | 43.1M | 48.7M | 48.1M | 49.1M |
| Operating Expenses | 59.8M | 50.2M | 72.4M | 55.6M | 53.4M |
| Depreciation & Amortization | 15.6M | 18M | 16M | 13.4M | 12.8M |
| EBITDA | 54.1M | 62.9M | 12.6M | 45.1M | 38.1M |
| EBITDA Margin | 14.5% | 14.9% | 3.1% | 11.5% | 9.9% |
| Operating Income | 36.2M | 44.8M | 4.2M | 30.1M | 35.8M |
| Operating Margin | 9.7% | 10.6% | 1.0% | 7.7% | 9.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.1M | 3.9M | 6.3M | 5.2M | 3.1M |
| Other Income / Expenses | (800K) | (3.8M) | (13.9M) | (3.6M) | (13.6M) |
| Income Before Tax | 35.4M | 41M | (9.7M) | 26.5M | 22.2M |
| Pre-Tax Margin | 9.5% | 9.7% | -2.4% | 6.8% | 5.8% |
| Income Tax Expense | 5.4M | 9M | (7.1M) | 8.2M | 9.1M |
| Net Income | 29.9M | 26.9M | (1.9M) | 18.4M | 7.7M |
| Net Margin | 8.0% | 6.4% | -0.5% | 4.7% | 2.0% |
| EPS (Basic) | 1.08 | 0.99 | (0.07) | 0.69 | 0.29 |
| EPS (Diluted) | 1.07 | 0.98 | (0.07) | 0.69 | 0.28 |
| Weighted Avg Shares | 27.7M | 27.3M | 26.9M | 26.81M | 26.73M |
| Weighted Avg Shares (Diluted) | 28.03M | 27.54M | 27.02M | 26.81M | 27.25M |
Luxfer Holdings PLC
NYSE:LXFR
Intrinsic Alpha fair value
Locked
Current Price
$17.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.